Table 2 Participant demographic and clinical characteristics (among patients who initiated ART between January 2020 and May 2021)

Sex

Female

2,435

(41.6%)

476

(46.5%)

1,959

(40.6%)

Male

3,416

(58.4%)

548

(53.5%)

2,868

(59.4%)

Age (mean, SD)

40.8

(9.2)

41.2

(9.1)

40.7

(9.2)

Facility type

City AIDS Center

672

(11.5%)

94

(9.2%)

578

(12.0%)

Regional AIDS Center

2,910

(49.7%)

421

(41.1%)

2,489

(51.6%)

Other ART site

2,269

(38.8%)

509

(49.7%)

1,760

(36.5%)

TB status (at time of ART initiation)

Confirmed

322

(5.7%)

40

(4.0%)

282

(6.1%)

Suspected

97

(1.7%)

13

(1.3%)

84

(1.8%)

No

5,227

(92.6%)

956

(94.7%)

4,271

(92.1%)

(Missing)

205

15

190

WHO HIV stage (at time of ART initiation)

Acute HIV infection

13

(0.2%)

3

(0.3%)

10

(0.2%)

Clinical stage 1

2,575

(44.1%)

503

(49.3%)

2,072

(43.0%)

Clinical stage 2

789

(13.5%)

135

(13.2%)

654

(13.6%)

Clinical stage 3

1,408

(24.1%)

233

(22.8%)

1,175

(24.4%)

Clinical stage 4

1,053

(18.0%)

147

(14.4%)

906

(18.8%)

(Missing)

13

3

10

CD4 value (at time of ART initiation)

>=500

1,293

(25.2%)

229

(25.0%)

1,064

(25.3%)

350–499

984

(19.2%)

198

(21.6%)

786

(18.7%)

200–349

1,170

(22.8%)

203

(22.1%)

967

(23.0%)

<200

1,677

(32.7%)

287

(31.3%)

1,390

(33.0%)

(Missing)

727

107

620

ART initiation timeliness

Same day

2,033

(36.9%)

466

(47.9%)

1,567

(34.6%)

1–7 days

1,279

(23.2%)

237

(24.4%)

1,042

(23.0%)

8–30 days

825

(15.0%)

164

(16.9%)

661

(14.6%)

31–60 days

157

(2.9%)

23

(2.4%)

134

(3.0%)

61–120 days

68

(1.2%)

10

(1.0%)

58

(1.3%)

> 120 days

1,146

(20.8%)

73

(7.5%)

1,073

(23.7%)

(Missing)

343

51

292